KONEXFood & Beverage178600

Daedong Korea Ginseng

₩1,699▼ 5.51%2026-11-18 close
Market Cap
₩7.6B
Turnover
₩5,200
Volume
3 shares
Shares out.
4.5M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Widening Beyond Red Ginseng

Daedong Korea Ginseng is adding new materials and formats to its red ginseng base and returned to profit in the June 2026 fiscal year.

  1. 1

    Revenue for the June 2026 fiscal year was KRW 45.4 billion and operating profit was KRW 1.94 billion, a 4.28% operating margin (JobKorea financial data).

  2. 2

    The KRW 1.418 billion net loss in the June 2025 fiscal year was the company's first since its founding.

  3. 3

    OEM and ODM sales account for more than 70% of the total, while the company's own brands supplement profitability.

  4. 4

    Revenue has declined for three consecutive fiscal years since KRW 48.35 billion in the June 2023 fiscal year.

  5. 5

    Treasury share cancellation in March 2026 and a KRW 3.0 billion convertible preferred share placement in April 2026 changed the capital structure.

02

Business structure

Daedong Korea Ginseng was founded in 2002 and listed on KONEX in 2013 as a processor of red and black ginseng. It buys ginseng directly and handles processing, drying, extraction and concentration in-house.

The business has two pillars: OEM and ODM supply of raw materials used in other companies' finished products, and branded products led by the Bulrogun and Jinssen names. Reports indicate OEM and ODM sales exceed 70% of the total.

Raw material sales provide a stable revenue base, while branded products are positioned to lift profitability.

Its core technology is a patented integrated concentration system that extracts active ingredients through short, low-temperature processing, reportedly cutting energy use to about one-tenth of conventional red ginseng concentration.

A three-stage drying process combining ceramic stone, ocher and charcoal, along with fermentation and enzyme treatment, supports high-function ginseng materials. The scope is widening to natural materials such as ginseng berries and mushrooms.

The company produces a individually recognized functional raw material aimed at easing menopausal symptoms, and a natural material targeting memory improvement is progressing through a functionality approval process.

Compared with large listed food and beverage companies, its scale is small, and its June 2025 fiscal year revenue placed it in the top 20% of its industry peers by size (Saramin financial data). Because the business leans toward B2B raw material supply, results are heavily tied to customer order volumes.

03

Recent trends

For the June 2025 fiscal year, revenue was KRW 45.73 billion and operating profit fell sharply to KRW 1.17 billion (Saramin and Catch financial data). The company posted a KRW 1.418 billion net loss, its first since founding, which reports attribute to investment in new production facilities.

In the June 2024 fiscal year, revenue was KRW 46.07 billion, operating profit KRW 2.43 billion and net income KRW 484 million, down from operating profit of KRW 5.19 billion in the June 2023 fiscal year.

For the June 2026 fiscal year (JobKorea financial data), revenue was KRW 45.4 billion and operating profit KRW 1.94 billion, with the operating margin rising from 2.57% to 4.28%. Net income turned positive at KRW 293.9 million. Revenue has edged down since 2023.

Operating cash flow was KRW 4.0 billion in the June 2026 fiscal year, up from KRW 3.18 billion a year earlier. The debt ratio was 153.59% and the equity ratio 39.43% at the same date, so leverage remains high.

On the capital side, treasury shares were acquired and cancelled in March 2026 following a redemption request on convertible preferred shares, and in April 2026 a third-party placement of 750,000 convertible preferred shares at KRW 4,000 per share, raising KRW 3.0 billion, was disclosed. Reports said the share price fell 11.86% on April 1, 2026 to KRW 1,762.

04

Outlook

The company's task is to widen a red ginseng-centered revenue base with new products such as individually recognized functional raw materials and pouch-type dual-format products.

The CEO said that efficiency gains in new product production and stronger sales growth could sustain the return to profitability, according to press reports.

The June 2026 fiscal year returned to profit, but revenue of KRW 45.4 billion remains below KRW 48.35 billion in the June 2023 fiscal year, so whether top-line recovery is keeping pace with profit improvement has not yet been demonstrated in the numbers.

Revenue was KRW 57.5 billion over the period from June 2019 to June 2020, a scale well above current levels. Lower tourist numbers and weaker demand for red ginseng have been cited as causes of the revenue decline.

Borrowings dependence was 52.06% in the June 2026 fiscal year, which leaves the company sensitive to interest rates and working capital financing conditions. Disclosures on convertible preferred shares continue, so further changes to the capital structure will surface through filings.

At the September 30, 2026 annual general meeting, all four agenda items, including approval of financial statements and a dividend resolution, passed.

The company's medium-term plan includes expanding online and mobile channels, widening presence in supermarkets and department stores, and increasing raw material supply to pharmaceutical and health functional food companies.

05

Bull factors

Raw material base and OEM/ODM weight

With OEM and ODM sales above 70% of the total, direct exposure to swings in finished-product distribution is comparatively limited. The Bulrogun and Jinssen brands add profitability on top of the raw material base.

The patented concentration system is reported to cut energy use to about one-tenth of conventional red ginseng concentration.

Return to profit in June 2026

Operating profit for the June 2026 fiscal year was KRW 1.94 billion, with the operating margin rising to 4.28% from 2.57% a year earlier. Net income moved from a loss in June 2025 to KRW 293.9 million. The CEO has said he expects profitability to hold as new production lines become more efficient.

Expansion into new materials and formats

The company is positioning individually recognized functional raw materials and pouch-type dual-format products as its next cash generators.

It already produces an individually recognized raw material for menopausal symptom relief, and a natural material aimed at memory improvement is in the functionality approval process. Its extraction and concentration technology is being applied to ginseng berries, mushrooms and other natural materials.

06

Bear factors

Shrinking top line

Revenue fell from KRW 48.35 billion in the June 2023 fiscal year to KRW 45.4 billion in the June 2026 fiscal year. Recovery has been slow compared with the KRW 57.5 billion scale reached between June 2019 and June 2020. Reduced tourist traffic and weaker interest in red ginseng have been cited as contributing factors.

First-ever loss and high leverage

The KRW 1.418 billion net loss in the June 2025 fiscal year was the company's first since founding and arose during new facility investment. The debt ratio was 170.49% in June 2025 and still 153.59% in June 2026. With borrowings dependence above 50%, financial headroom is limited.

Capital raising and share price volatility

Following a redemption request on convertible preferred shares, the company acquired and cancelled treasury shares in March 2026. In April 2026, a placement of 750,000 convertible preferred shares at KRW 4,000 per share, raising KRW 3.0 billion, was disclosed.

The share price fell 11.86% on April 1, 2026, and the 52-week range as of August 6, 2026 was KRW 1,352 to KRW 2,840.

07

Risk factors

Macro

Red ginseng demand is tied to household spending and travel, and lower tourist traffic has been cited as a factor in revenue decline. Interest rates and raw material prices could weigh on the company given its reliance on borrowings. Because it purchases ginseng directly, crop conditions and prices feed quickly into costs.

Regulatory

Functionality approval for individually recognized raw materials and a natural memory-related material is still in progress, and timing and outcomes remain uncertain. Changes in functional labeling rules for health functional foods could affect product mix and sales plans. Delays in approval could slow the pace of the shift to new products.

Market and liquidity

The company is listed on KONEX, where trading volumes tend to be small and price swings can be wide. Repeated convertible preferred share issuance and treasury share cancellation keep the share count and ownership structure changing. The share price's sharp one-day fall of 11.86% in April 2026 illustrates the short-term volatility.

08

Overall view

Daedong Korea Ginseng is adding new materials and formats on top of a business built around red and black ginseng raw materials and OEM and ODM supply. Operating and net income were both positive for the June 2026 fiscal year, reversing the loss pattern seen in June 2025.

Revenue, however, has declined since the June 2023 fiscal year and remains below the KRW 57.5 billion scale of June 2019 to June 2020. A debt ratio above 150% and repeated capital measures, including convertible preferred share issuance and treasury share cancellation, are key points on the financial side.

On the strengths side, the raw material base, the patented concentration technology and the individually recognized raw material lineup stand out. On the weaknesses side, flat revenue, a loss history tied to facility investment and limited liquidity on KONEX stand out.

Results from the company's online channel and export expansion plans will appear in future business reports and quarterly disclosures. This is a qualitative summary for informational purposes only.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. hankyung.com
  2. jobkorea.co.kr
  3. saramin.co.kr
  4. catch.co.kr
  5. digitaltoday.co.kr
  6. m.news.nate.com
  7. kr.investing.com
  8. digitaltoday.co.kr
  9. investing.com
  10. v.daum.net
  11. m.irgo.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis